

With Cirrhosis

TABLE 99: SVR GENOTYPE 1 TREATMENT-NAIVE WITH CIRRHOSIS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 + SOF12	PR48	2.18 (0.93 to 2.95)	48.42 (−2.57 to 63.34)
T12 PR24-48 RGT q8		1.43 (0.64 to 2.20)	17.16 (−14.64 to 42.87)
T12 PR24-48 RGT q12		1.55 (0.56 to 2.32)	21.73 (−17.87 to 47.59)
SOF12 + PR12		2.04 (1.13 to 2.75)	41.98 (5.31 to 58.28)
SIM12 PR24-48 RGT		1.70 (1.06 to 2.39)	27.76 (2.43 to 47.38)
B24 PR28-48 RGT		0.65 (0.16 to 1.65)	−13.87 (−36.76 to 23.90)
SOF12 + SIM12 + RBV12		2.24 (0.67 to 3.01)	51.36 (−13.09 to 65.16)
SOF24 + RBV24		1.76 (0.62 to 2.57)	30.39 (−15.42 to 54.59)
DCV24 + ASU24		2.25 (1.66 to 2.96)	50.01 (29.20 to 62.29)
SOF12 + LDV12		2.41 (1.89 to 3.09)	56.09 (41.08 to 65.83)
SOF12 + LDV12 + RBV12		2.41 (1.92 to 3.10)	56.29 (42.82 to 66.03)
SOF24 + LDV24 + RBV24		2.42 (1.89 to 3.11)	56.60 (41.16 to 66.35)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR24-48 RGT q8	SIM12 + SOF12	0.67 (0.32 to 1.40)	-28.47 (-60.87 to 15.94)
T12 PR24-48 RGT q12		0.73 (0.28 to 1.55)	-24.07 (-63.46 to 22.55)
SOF12 + PR12		0.94 (0.60 to 1.89)	-5.26 (-34.84 to 35.34)
SIM12 PR24-48 RGT		0.78 (0.49 to 1.85)	-19.25 (-47.89 to 32.75)
B24 PR28-48 RGT		0.31 (0.08 to 0.96)	-58.53 (-87.04 to -1.96)
SOF12 + SIM12 + RBV12		1.02 (0.41 to 1.90)	1.85 (-43.91 to 40.09)
SOF24 + RBV24		0.82 (0.31 to 1.83)	-15.67 (-61.01 to 33.66)
DCV24 + ASU24		1.01 (0.79 to 2.41)	1.20 (-19.74 to 52.62)
SOF12 + LDV12		1.08 (0.90 to 2.58)	6.74 (-9.24 to 58.73)
SOF12 + LDV12 + RBV12		1.08 (0.92 to 2.59)	6.99 (-7.82 to 58.99)
SOF24 + LDV24 + RBV24		1.08 (0.91 to 2.59)	7.47 (-8.76 to 59.26)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.07 (0.63 to 1.60)	3.90 (-18.53 to 23.50)
SOF12 + PR12		1.41 (1.05 to 2.40)	23.09 (2.95 to 44.01)
SIM12 PR24-48 RGT		1.19 (0.66 to 2.74)	10.58 (-25.23 to 47.83)
B24 PR28-48 RGT		0.47 (0.11 to 1.48)	-29.09 (-64.23 to 16.74)
SOF12 + SIM12 + RBV12		1.51 (0.54 to 3.31)	30.74 (-27.68 to 65.72)
SOF24 + RBV24		1.20 (0.61 to 2.03)	11.49 (-18.83 to 37.99)
DCV24 + ASU24		1.57 (1.03 to 3.57)	32.25 (2.54 to 65.96)
SOF12 + LDV12		1.68 (1.14 to 3.77)	38.52 (11.05 to 71.05)
SOF12 + LDV12 + RBV12		1.68 (1.15 to 3.78)	38.69 (12.22 to 70.83)
SOF24 + LDV24 + RBV24		1.69 (1.15 to 3.78)	39.17 (11.68 to 71.29)
SOF12 + PR12	T12 PR24-48 RGT q12	1.31 (0.90 to 2.90)	19.08 (-6.71 to 48.45)
SIM12 PR24-48 RGT		1.11 (0.62 to 3.10)	6.53 (-29.83 to 49.07)
B24 PR28-48 RGT		0.44 (0.11 to 1.54)	-33.27 (-68.97 to 16.13)
SOF12 + SIM12 + RBV12		1.41 (0.49 to 3.64)	26.29 (-31.88 to 67.55)
SOF24 + RBV24		1.12 (0.72 to 1.81)	7.14 (-14.71 to 29.66)
DCV24 + ASU24		1.45 (0.98 to 4.05)	27.46 (-1.39 to 68.54)
SOF12 + LDV12		1.55 (1.08 to 4.33)	33.81 (6.73 to 74.10)
SOF12 + LDV12 + RBV12		1.56 (1.09 to 4.31)	34.02 (7.53 to 73.83)
SOF24 + LDV24 + RBV24		1.56 (1.08 to 4.34)	34.64 (6.91 to 73.92)
SIM12 PR24-48 RGT	SOF12 + PR12	0.84 (0.52 to 1.52)	-13.54 (-43.12 to 24.99)
B24 PR28-48 RGT		0.32 (0.08 to 0.89)	-53.63 (-81.32 to -6.62)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + SIM12 + RBV12		1.09 (0.37 to 1.84)	7.61 (-48.56 to 42.61)
SOF24 + RBV24		0.86 (0.37 to 1.32)	-11.14 (-47.24 to 17.75)
DCV24 + ASU24		1.09 (0.84 to 1.98)	7.47 (-14.92 to 45.15)
SOF12 + LDV12		1.16 (0.94 to 2.10)	13.31 (-5.23 to 50.44)
SOF12 + LDV12 + RBV12		1.16 (0.97 to 2.09)	13.41 (-2.51 to 50.15)
SOF24 + LDV24 + RBV24		1.17 (0.96 to 2.11)	13.87 (-3.73 to 50.57)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	0.38 (0.09 to 1.11)	-41.16 (-70.59 to 5.57)
SOF12 + SIM12 + RBV12		1.31 (0.40 to 2.10)	21.68 (-41.38 to 50.57)
SOF24 + RBV24		1.03 (0.36 to 1.77)	2.00 (-45.42 to 37.74)
DCV24 + ASU24		1.32 (0.95 to 2.10)	21.69 (-4.18 to 48.67)
SOF12 + LDV12		1.41 (1.08 to 2.20)	27.99 (6.69 to 52.83)
SOF12 + LDV12 + RBV12		1.41 (1.09 to 2.22)	28.14 (7.70 to 53.42)
SOF24 + LDV24 + RBV24		1.42 (1.08 to 2.21)	28.55 (6.56 to 53.00)
SOF12 + SIM12 + RBV12	B24 PR28-48 RGT	3.26 (0.89 to 13.53)	61.17 (-3.66 to 89.85)
SOF24 + RBV24		2.58 (0.71 to 10.54)	41.94 (-12.56 to 76.49)
DCV24 + ASU24		3.50 (1.38 to 13.59)	63.37 (22.73 to 85.94)
SOF12 + LDV12		3.75 (1.49 to 14.52)	69.80 (29.96 to 90.37)
SOF12 + LDV12 + RBV12		3.76 (1.51 to 14.45)	70.11 (31.63 to 90.20)
SOF24 + LDV24 + RBV24		3.77 (1.50 to 14.50)	70.30 (30.99 to 90.43)
SOF24 + RBV24	SOF12 + SIM12 + RBV12	0.81 (0.30 to 2.29)	-17.55 (-65.49 to 42.06)
DCV24 + ASU24		0.98 (0.77 to 3.31)	-1.70 (-22.52 to 62.71)
SOF12 + LDV12		1.04 (0.88 to 3.56)	3.40 (-12.04 to 68.71)
SOF12 + LDV12 + RBV12		1.04 (0.90 to 3.57)	3.51 (-9.80 to 68.91)
SOF24 + LDV24 + RBV24		1.04 (0.88 to 3.59)	4.04 (-11.29 to 69.86)
DCV24 + ASU24	SOF24 + RBV24	1.27 (0.90 to 3.67)	19.02 (-8.53 to 66.42)
SOF12 + LDV12		1.36 (1.00 to 3.88)	24.98 (0.09 to 71.25)
SOF12 + LDV12 + RBV12		1.36 (1.01 to 3.88)	25.26 (0.77 to 71.88)
SOF24 + LDV24 + RBV24		1.36 (1.00 to 3.89)	25.64 (0.28 to 71.67)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12	DCV24 + ASU24	1.07 (0.90 to 1.35)	5.83 (−9.18 to 24.72)
SOF12 + LDV12 + RBV12		1.07 (0.92 to 1.35)	6.01 (−7.56 to 24.96)
SOF24 + LDV24 + RBV24		1.07 (0.91 to 1.34)	6.35 (−8.01 to 24.71)
SOF12 + LDV12 + RBV12	SOF12 + LDV12	1.00 (0.91 to 1.13)	0.06 (−8.70 to 10.50)
SOF24 + LDV24 + RBV24		1.00 (0.88 to 1.15)	0.39 (−11.38 to 12.54)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.00 (0.88 to 1.13)	0.32 (−11.85 to 11.01)
Random effect model	Residual deviance	26.88 vs. 30 data points	
	Deviance information criteria	141.592	
Fixed effect model	Residual deviance	26.53 vs. 30 data points	
	Deviance Information Criteria	140.778	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.